UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): November 12, 2021

 

ONCOSEC MEDICAL INCORPORATED

(Exact Name of Registrant as Specified in Charter)

 

Nevada   000-54318   98-0573252

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

24 North Main Street

Pennington, NJ 08534-2218

(Address of Principal Executive Offices)

 

(855) 662-6732

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  Written communications pursuant to Rule 425 under the Securities Act.
     
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
     
  Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
     
  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading

Symbol(s)

  Name of each exchange on which registered
Common Stock, par value $0.0001 per share   ONCS   NASDAQ Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 7.01. Regulation FD Disclosure

 

On Friday, November 12, 2021, OncoSec Medical Incorporated (the “Company”) hosted a Key Opinion Leader Symposium via conference call and webinar. The event provided a discussion on the clinical relevance of and updated data from the Company’s KEYNOTE-695 study of tavokinogene telseplasmid (“TAVO”), the Company’s lead product candidate, which was also presented in a poster at the Society for Immunotherapy of Cancer 2021 Annual Meeting.

 

The poster, PowerPoint slides, and other information presented, as well as a recording of the webinar, can be found on the Company’s website at www.oncosec.com.

 

In accordance with General Instruction B.2 of Form 8-K, the information disclosed in Item 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing. This Current Report on Form 8-K does not constitute a determination of whether any information included herein is material.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ONCOSEC MEDICAL INCORPORATED
  (Registrant)
   
Date: November 15, 2021    
     
  By: /s/ Dr. Margaret Dalesandro
  Name: Dr. Margaret Dalesandro
  Title: Interim Principal Executive Officer and Chair of the Board

 

 

 

 

OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more OncoSec Medical Charts.
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more OncoSec Medical Charts.